We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Magnetic Probe Guides Surgical Breast Lumpectomy

By HospiMedica International staff writers
Posted on 12 Oct 2016
A novel magnetic surgical guidance probe uses an implantable lesion marker to easily guide surgeons to cancerous lesions.

The Sentimag+Magseed combination device is a novel surgical guidance system designed to replace surgical wire needles and radioactive seeds, the two standards of care currently in practice for finding a breast tumor in advance of a lumpectomy. More...
The Magseed implantable magnetic marker, a spiral shaped coil the size of a grain of rice, is first placed within the tumor in an outpatient procedure up to 30 days before the lumpectomy, allowing patients to return home before their operation.

During the lumpectomy, the Sentimag device is used to provide ultrasensitive, intuitive detection of the tumor, based on the principle of magnetic susceptometry. It does so by first generating an alternating magnetic field to transiently magnetize the iron oxide particles in the Magseed, and then detecting the tiny magnetic signature. Guided by the large two-color digital display and by an audible pitch variation, the surgeon can focus on the patient, not the device.

The Sentimag device boasts extremely high on-axis sensitivity for naturally intuitive and accurate node location. Sensitivity is adjustable in three settings from a control on the front panel, making it capable of detecting even minute quantities of magnetic material in the body. The Sentimag+Magseed combination device is a product of Endomag (Cambridge, United Kingdom), and has been approved by the U.S. Food and Drug Administration (FDA).

“Magseed is designed to guide surgeons using Sentimag to locate impalpable tumors for biopsy and has many advantages over wire and radioactive seed localization,” said device co-inventor professor Audrius Brazdeikis, PhD, a physicist at the University of Houston (UH, TX, USA). “Radiologists can place the Magseed magnetic markers up to 30 days in advance of surgery using X-ray or ultrasound guidance. This offers scheduling flexibility for surgeons and radiologists, as well as for patients, compared to wire-guided localization.”

Current lumpectomies require traditional guide wires inserted by a radiologist in a separate procedure prior to the procedure. The wires protrude from the patient’s breast, leading to potential discomfort and restricting the patient to the hospital environment. More critically, the protruding guide wires risk movement prior to surgery, requiring follow-up surgery in up to 55% of lumpectomy procedures.

Related Links:
Endomag
University of Houston

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.